ENDO RECEIVES FDA APPROVAL FOR EXTENDED-RELEASE AND IMMEDIATE-RELEASE OPANA TABLETS (oxymorphone HCl) CII

New Oral Opioid Analgesic Soon to Become Commercially Available in the U.S.

Story Summary:

Chronic Pain is a Public Health Issue. It’s estimated that pain costs the U.S. more than $100 billion annually in healthcare expenditures and lost productivity. In fact, research shows pain contributes to more than 50 million lost workdays each year. Although data suggest that pain is often undertreated, experts agree that chronic pain patients need around-the-clock coverage with an analgesic agent to sustain pain relief

Chronic Pain Patients Need New Treatment Options. As the population ages, the number of people who will need treatment for pain – from back disorders, degenerative joint disease, visceral diseases, and cancer – is expected to rise. Approximately 10% of Americans suffer from moderate-to-severe chronic pain. Additionally, physicians often need to rotate opioids in order to effectively manage a patient's chronic pain because patients can develop tolerance to a particular treatment.

• OPANA® ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid therapy for an extended period of time and is not intended to be used on an as-needed basis.
• OPANA® is indicated for the relief of moderate-to-severe pain where the use of an opioid is appropriate.
• The clinical program for Opana® ER and Opana® represents one of the most comprehensive ever conducted for an opioid analgesic.

Soundbites

• Richard Rauck, M.D., Clinical Associate Professor in the Department of Anesthesiology at Wake Forest University School of Medicine
• Peter A. Lankau, President and CEO, Endo Pharmaceuticals Inc.

B-Roll Includes

• Doctor/Patient B-roll
• Corporate Headquarters

VIDEO PROVIDED BY: "Endo Pharmaceuticals Inc."